Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australia to revise device evaluation fees:

This article was originally published in Clinica

Executive Summary

A revised schedule of premarket evaluation fees is to be introduced by the Australian Therapeutic Devices Branch (TDB) during 1995. The fees will be established according to the level of equivalence to a previously evaluated and currently registered device. The greater the equivalence, the lower the fee, according to the Australian Therapeutic Device Bulletin. It will therefore be vital for companies to submit properly developed tables of equivalence in support of product applications, says the TDB. In the case of applications which are received concurrently and which are capable of simultaneous evaluation, the fee charged will be one-third of the normal fee in each category for each of the applications apart from the first.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT090571

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel